Vutrisiran is already approved as Amvuttra to treat polyneuropathy caused by ATTR, but extending its indications to include ...

Since the turn of the decade, the pharmaceuticals industry has dealt with supply chain challenges caused by both the pandemic ...

Among all the changes happening in the healthcare landscape in the last few years, the advent of digital health technology stands out as one poised to fuel innovation and revolutionise healthcare ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

An FDA advisory committee has voted in favour of approving AstraZeneca and Sanofi’s one-shot antibody treatment to prevent respiratory syncytial virus (RSV) disease in infants, several months ...

CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its competitor’s products.

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futile. The KeyVibe-010 ...

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...

In the pharma-adjacent, pharma supplier, and digital health worlds, we saw a significant number of hires in May and June. Benchling nabs two heavy-hitters for C-Suite. San Francisco-based R&D ...

There is a lot, and I mean a lot, of discussion right now about the potential for artificial intelligence (AI) to transform the pharmaceutical industry (as, indeed, there is across all industries).

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...